

# Cancer Partnering Day – The fields of interest of the attending 11 Global Pharma companies

*Please read carefully what the attending global pharmaceutical companies are looking for, to identify how they could benefit from the products, services and innovations your organization has to offer.*

## Global Pharma Partners

|  |           |
|--|-----------|
| <b>AbbVie .....</b>  | <b>2</b>  |
| <b>AstraZeneca .....</b>   | <b>3</b>  |
| <b>Bristol Myers Squibb .....</b>                                      | <b>4</b>  |
| <b>Janssen, Pharmaceutical Companies of Johnson &amp; Johnson.....</b> | <b>5</b>  |
| <b>Merck (KGaA).....</b>   | <b>6</b>  |
| <b>MSD .....</b>   | <b>7</b>  |
| <b>Novartis .....</b>  | <b>8</b>  |
| <b>Orion.....</b>  | <b>9</b>  |
| <b>Pfizer.....</b>   | <b>10</b> |
| <b>Roche.....</b>  | <b>11</b> |
| <b>Takeda .....</b>  | <b>12</b> |

## AbbVie

*Our goal is to transform the way cancer is treated. AbbVie is committed to discovering and developing therapies that work against the processes that cancer cells need to survive. We are committed to achieving long-term control of hematologic malignancies, and investing to identify and advance promising therapies for solid tumors.*

### **Our areas of interest include:**

- Novel and differentiated programs directed towards enhanced tumor cell targeting, oncogenic signaling pathways and immuno-oncology
- Targeted biologics and next generation cell therapies
- Novel approaches to small molecules, including technologies to address hard-to-drug target classes

## AstraZeneca

**The interest areas from an Oncology R&D perspective include:**

Therapies and data/precision medicine approaches for oncology (aligned to but not exclusively the following cancers: lung, breast, ovarian, gastrointestinal, genitourinary) in the following areas:

- Tumor drivers and resistance mechanisms
- DNA Damage Response
- Epigenetics
- Immuno-oncology (including engager and cell therapy approaches)
- Antibody drug conjugates and associated technologies

## Bristol Myers Squibb

### **Solid Tumor Oncology Areas of Interest:**

- Therapies that address tumor intrinsic vulnerabilities and primary or acquired mechanisms of resistance to standard of care
- Tumor intrinsic biology with clear patient selection strategy
- New modalities including antibody-drug conjugates, immune cell engagers, and protein degraders
- Historically intractable targets to develop disruptive therapeutic technologies
- Novel innate and adaptive immune mechanisms
- Novel therapies that transform response rates and durability for patients

### **Hematology Areas of Interest:**

- Protein homeostasis/ degradation
- Epigenetics
- ADCs, immune cell engagers, and other novel antibody constructs
- Targeting molecularly defined patient segments
- Next generation therapies with differentiated safety and efficacy profiles
- Novel therapeutic targets/ pathways and combinations
- Targeting pathways of resistance

### **Cell Therapy Areas of Interest:**

- Our focus is to broaden the impact of cell therapy in oncology across heme and solid tumors and researching potential next-generation CAR-Ts that focus on new targets and utilize new technologies.
- Non-viral delivery for modifying cell gene expression
- Enabling manufacturing platforms and technologies
- Combinations with other therapies to increase efficacy

## Janssen, Pharmaceutical Companies of Johnson & Johnson

### **The interest areas of Janssen oncology include:**

- Haematological malignancies (B-cell, multiple myeloma and myeloid)
- Lung cancer
- Bladder cancer
- Colorectal cancer
- Prostate cancer
- Immune-oncology

We work across a range of modalities, including but not limited to small molecules, antibody based technologies, vaccines and cell therapies across a range of development stages with assets at candidate stage and beyond of particular interest.

## Merck (KGaA)

*Merck Healthcare's search scope across franchises focuses on PoC-stage and close to market opportunities for clinical stage assets.*

### **Our areas of interest in oncology and immuno-oncology include:**

- Focus tumortypes: SCCHN, Lung (NSCLC, SCLC), GU, GI/CRC, Gyn
- Oncogenic signaling
- DNA damage response
- T-& NK-cellbiology
- Myeloid-cell biology
- Protein-stress response
- Developmental pathways
- ADCs
- Targeted-protein degraders

**Not in scope:** Hemato-Oncology

## MSD

### **The interest areas of MSD include:**

#### **Immuno-oncology**

- Targets that are known to underlie the action of current IO agents
- Tumor microenvironment
- Tumor stroma
- Myeloid/fibroblast driven suppression
- NK/Gamma delta T cell activation

#### **Tumor intrinsic targets**

- Targeting mutant oncogenes required for tumor growth
- Targets in defined tumor genetic contexts
- Tumor targets where dependency is revealed in the context of other active molecules
- Targets that have synergy or overcome resistance to pipeline assets

#### **ADCs and redirected cell killing**

- Improved tumor targeting
- Novel payloads
- Technologies to improve therapeutic index and broaden indications

#### **Platforms**

- Targeted protein degradation
- Machine learning/AI approaches

## Novartis

### List of Novartis main interest areas with examples of topics:

#### Lung cancer

- MET genetics (dysregulation, MET-ex-14, amplification)
- KRAS G12C
- ctDNA, liquid biopsies

#### Prostate cancer

- All stages
- Biomarkers for treatment evidence (RWE, translational...)

#### Breast

- PIK3C and mTOR pathways
- TNBC

#### Immune infiltration in solid tumors

- Methods and analysis
- Biomarkers

#### TPD (Targeted Protein Degradation)

#### RWE data solutions

- Novel solutions to improve optimal usage of RWE to facilitate treatment decisions in oncology clinics
- Solutions to facilitate patient engagement in their own health data and usage, including self reported outcomes
- Linkage of pathology and/or imaging datasets with clinical outcomes including technologies to advance prediction of clinical outcomes or identification of specific mutations from tissue imaging.
- AI precision pathology



## Orion

### **Research Focus areas:**

- Immuno-oncology
- DNA repair and other synthetic lethalties as basis for biomarker-guided cancer drug discovery
- Oncogenic signaling and tumor cell metabolism
- Cell surface tumor-associated antigens preferentially expressed in tumors versus non-malignant tissues

*Drug targets should have human genetic or pharmacological validation data*

### **Technologies:**

- Models and assays related to the research focus areas
- Novel strategies for screening new targets in relevant cancer models
- Novel strategies for modulating validated cancer targets
- CART cell therapies
- Use of data science / bioinformatics / AI for identification of cancer new targets

## Pfizer

### **Pfizer is seeking partnering opportunities in:**

- Alteration of tumor evolution to prevent drug treatment resistance:
  - Seeking targets involved in cancer cell mutagenesis, drivers of lineage plasticity, and the emergence of drug tolerant persister cells (DTPs)
- Transcription Factors: Novel oncogenic transcription factors and their complexes, as well as new mechanisms for their modulation
- RNA-based in vivo cellular reprogramming -> RNA therapeutics

*Note: Pfizer is not seeking partnering opportunities in:*

- *Cell-based therapies*
- *Proposals for repurposing of existing drugs for new/ additional indications*
- *Antibody-drug conjugates (ADCs)*
- *Rare tumor indications*

## Roche

### **Areas of interest:**

#### **Pharma/Diagnostics**

#### **(Examples include but are not limited to)**

- Applications of clinico-genomic real-world data (data anonymization, data models, clinico-genomic data, clinical decision support)
- Digital health solutions / Digital service solution (treatment monitoring, remote monitoring, patient reported outcomes)
- Digital pathology (image analysis)
- Molecular tumor boards / multidisciplinary team solutions
- Identification of digital biomarkers/ Identification of biomarkers
- Early diagnosis utilizing data capture and access, AI
- Advanced data analysis
- Integration of existing data platforms
- Patient engagement

## Takeda

### **Therapeutic areas**

- Multiple Myeloma
- Lung Cancer
- Lymphomas and CD19+ Hematologic Malignancies
- Multiple other Cancers

### **Solution areas**

- AI
- Digital Health
- Early diagnosis
- Clinical decision-making support
- Treatment response monitoring
- Integrated care solutions
- Personalized treatment
- Digital biomarkers
- Real World Evidence, Health Data, Clinical Biobanks, Registry Studies